pLP-LNCX-PIK3CA-WT Citations (2)

Originally described in: Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T Mol Cell Biol. 2007 Jan . 27(2):662-77. PubMed Journal

---

Articles Citing pLP-LNCX-PIK3CA-WT

Articles
Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Sci Signal. 2017 Feb 21;10(467). pii: 10/467/eaah4674. doi: 10.1126/scisignal.aah4674. PubMed
Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. DuBose E, Bevill SM, Mitchell DK, Sciaky N, Golitz BT, Dixon SAH, Rhodes SD, Bear JE, Johnson GL, Angus SP. Front Oncol. 2024 May 16;14:1191217. doi: 10.3389/fonc.2024.1191217. eCollection 2024. PubMed

If you have published an article using this material, please email us at to have your article added to this page.